FDA approves Salix's diarrhea drug for HIV/AIDS patients
Dec 31 (Reuters) - U.S. health regulators approved Salix Pharmaceuticals Ltd's drug to treat diarrhea in HIV/AIDS patients on antiretroviral therapy, a combination of medicines used to treat HIV infection.
Diarrhea is a common reason why HIV/AIDS patients discontinue or switch their antiretroviral therapies.
The drug, called Fulyzaq, is intended to be used in HIV/AIDS patients whose diarrhea is not caused by an infection from a virus, bacteria, or parasite.
Until now, there have been no therapies for HIV-associated diarrhea approved by the U.S. Food and Drug Administration.
- U.S.' Kerry voices 'regret' to India over diplomat case |
- Washington, DC city council raises minimum wage to $11.50/hr in 2016
- China confirms near miss with U.S. ship in South China Sea
- Mega Millions winners in Georgia, California to split $648 million |
- Medical bills underlie 60 percent of U.S. bankrupts: study